Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 84

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 84
---
 net tangible book value would have been $0.18 per share. This represents an immediate increase in net tangible book value of $0.09 per share to existing stockholders and an immediate dilution in net tangible book value of $0.299 per share to investors purchasing securities in this offering at the assumed offering price.

The following table illustrates the dilution on a per share basis:

| Assumed public offering price per share                              |     |   |      |     | $ | 0.499 |
| Historical net tangible book value per share as of December 31, 2024 |     | $ | 0.03 |     |   |       |
| Pro forma net tangible book value per share                          |     | $ | 0.09 |     |   |       |
| Increase in pro forma net tangible book value                        
 per share attributable to this offering                              |     | $ | 0.09 |     |   |       |
| Pro forma as adjusted net tangible book value                        
 per share after this offering                                        |     |   |      |     | $ |  0.18 |
| Dilution in net tangible book value per share                        
 to new investors in this offering                                    |     |   |      |     | $ | 0.319 |

Each $0.10 increase (decrease) in the assumed public offering price of $0.499 per share of Common Stock and accompanying May 2025 Warrant would increase (decrease) the as adjusted net tangible book value by $684,000 per share of Common Stock and the dilution to new investors by $0.319 per share, after deducting the estimated Placement Agent fees and estimated offering expenses payable by us.

We may also increase or decrease the number of shares we are offering. An increase of 1,000,000 shares in the number of shares of Common Stock offered by us would increase our as adjusted net tangible book value by approximately $0.5 million, or approximately $0.01 per share of Common Stock, and decrease the dilution per share to investors in this offering by approximately $0.01 per share, assuming that the number of shares of Common Stock and accompanying May 2025 Warrants offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated Placement Agent fees and estimated offering expenses payable by us. Similarly, a decrease of 1,000,000 shares in the number of shares of Common Stock offered by us